Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in Chronic Rhinosinusitis with Nasal Polyps
NCT03280550Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2017
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of omalizumab in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Roche. Started Nov 2017; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT03280550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03280550.